

1 **Title:** Rate of Antibiotic Use and Associated Risk Factors in COVID-19 Hospitalized Patients

2 **Running title:** COVID-19 antibiotic risk factors

3 **Authors:** Alysa J. Martin, PharmD¹; Stephanie Shulder, PharmD¹; David Dobrzynski, MD²;
4 Katelyn Quartuccio, PharmD³; Kelly E. Pillinger, PharmD¹

5 ¹ University of Rochester Medical Center Strong Memorial Hospital, Department of Pharmacy, Rochester, NY, USA

6 ² University of Rochester Medical Center, Division of Infectious Diseases, Rochester, NY, USA

7 ³ University of Rochester Medical Center Highland Hospital, Department of Pharmacy, Rochester, NY, USA

8

9 **Acknowledgements:**

10 The authors thank Raquel Roberts, PharmD for her assistance with data collection. There was
11 no funding for the study.

12

13 **Conflict of Interest Statement:** The authors have no personal conflicts of interests to disclose.

14 The authors would like to disclose that K. Quartuccio's spouse consults for AstraZeneca.

15

16 **Key words:** COVID-19, antimicrobial stewardship, antibiotics, community-acquired pneumonia,
17 bacterial infection

18

19

20

21

22

23

24 **Abstract**

25 **Background-** Literature suggests that antibiotic prescribing in COVID-19 patients is high, despite
26 low rates of confirmed bacterial infection. There are little data on what drives prescribing
27 habits.

28 **Objective-** This study sought to determine antibiotic prescribing rates and risk factors for
29 antibiotic prescribing in hospitalized patients. It was the first study to assess risk factors for
30 receiving more than one course of antibiotics.

31 **Methods-** This was a retrospective, multi-center, observational study. Patients admitted from
32 March 1, 2020 to May 31, 2020 and treated for PCR-confirmed COVID-19 were included. The
33 primary endpoint was the rate of antibiotic use during hospitalization. Secondary endpoints
34 included risk factors associated with antibiotic use, risk factors associated with receiving more
35 than one antibiotic course, and rate of microbiologically confirmed infections.

36 **Results-** A total of 208 encounters (198 patients) were included in the final analysis. Eighty-
37 three percent of patients received at least one course of antibiotics, despite low rates of
38 microbiologically confirmed infection (12%). Almost one-third of patients (30%) received more
39 than one course of antibiotics. Risk factors identified for both antibiotic prescribing and
40 receiving more than one course of antibiotics were more serious illness, increased hospital
41 length of stay, intensive care unit admission, mechanical ventilation, and acute respiratory
42 distress syndrome.

43 **Conclusion and relevance** – There were high rates of antibiotic prescribing with low rates of
44 bacterial co-infection. Many patients received more than one course of antibiotics during

45 hospitalization. This study highlights the need for increased antibiotic stewardship practices in

46 COVID-19 patients.

47

48

49

50 Introduction

51 The novel coronavirus disease identified in 2019 (COVID-19) is caused by a
52 betacoronavirus known as SARS-CoV-2. Despite the fact that COVID-19 is a viral infection,
53 clinical manifestations may present similarly to a bacterial pneumonia.¹ Patients often present
54 with respiratory symptoms including fever, cough, dyspnea, and bilateral changes on chest
55 imaging.¹ It can be difficult to determine if patients have a bacterial respiratory coinfection
56 along with COVID-19 infection. This may lead to over-prescribing of antibiotics in patients with
57 COVID-19.

58 Despite bacterial coinfection being reported in 2-8% of patients, rates of antibiotic
59 prescribing have ranged from 57-95% in hospitalized patients.¹⁻⁷ Additionally, there are reports
60 of increased consumption of antibiotics during the COVID-19 pandemic.⁶⁻⁹ Over-prescribing of
61 antibiotics may increase the risk of adverse side effects, nosocomial infection, and antibiotic
62 resistance. Several organizational guidelines recommend starting empiric antibiotic therapy if
63 concern for bacterial pneumonia or sepsis, but to re-evaluate daily and de-escalate or
64 discontinue if no evidence of bacterial infection.¹⁰⁻¹⁴ Furthermore, they emphasize the
65 importance of antimicrobial stewardship programs which may help to avoid starting antibiotics
66 reflexively or continuing unnecessary courses. The World Health Organization (WHO) has
67 released guidance which discourages the use of antibiotic therapy for patients with COVID-19
68 infections unless signs and symptoms of a bacterial infection exist.¹¹

69 Unfortunately, there are limited data to date describing the need or role for antibiotics
70 in COVID-19 or outcomes for patients who receive them. Additionally, little is known regarding

71 risk factors associated with antibiotic use. There have only been two previous studies which
72 evaluated prescribing trends and risk factors of antibiotic prescribing. Both studies focused on
73 prescribing rates, coinfections, and risk factors associated with antibiotic prescribing within the
74 first 48 hours of admission.^{4,5}

75 The purpose of this study was to evaluate the rate of antibiotic use in COVID-19 patients
76 and risk factors associated with antibiotic use throughout hospitalization. A better
77 understanding of prescribing practices can be used to evaluate opportunities for antibiotic
78 stewardship for future patients with COVID-19.

79 **Methods**

80 *Study design*

81 This was a multi-center, retrospective, observational study of antibiotic prescribing
82 trends in patients with confirmed COVID-19 at three hospitals within the University of
83 Rochester Medical Center.

84 Patients 18 years and older admitted from March 1, 2020 to May 31, 2020 and treated
85 for PCR-confirmed COVID-19 were eligible for inclusion. Patients did not meet inclusion criteria
86 if they were only treated in the emergency department without subsequent admission. Patients
87 could be included more than once if they had multiple admissions within the study period.

88 Patients were excluded if they were asymptomatic. Data were collected until June 30, 2020.

89 This study was reviewed and deemed exempt by the Institutional Review Board.

90 *Data Collection*

91 Patients were identified from the electronic health record based on a reported positive
92 SARS-CoV-2 PCR test. Baseline data including age, gender, race, weight, height, comorbidities,
93 date of first positive SARS-CoV-2 PCR, and admission and discharge dates were collected. Labs
94 on admission (or at time of positive test if nosocomial transmission), microbiologic data, clinical
95 symptoms, imaging, antibiotic data, COVID-19 investigational or off-label treatment, death and
96 re-admission within 30 days were also collected.

97 *Outcomes*

98 The primary endpoint of the study was the rate of antibiotic use in patients admitted for
99 COVID-19. Secondary endpoints included risk factors associated with antibiotic use, risk factors
100 associated with receiving more than one antibiotic course, and rate of microbiologically-
101 confirmed infections. Microbiologically-confirmed infection was defined as a positive result
102 from positive urinary antigens or respiratory and blood cultures not suggestive of contaminant
103 or colonization.

104 *Statistical Analysis*

105 Data were analyzed using R statistical software version 4.0.2 (Boston, MA) with a p-
106 value < 0.05 considered statistically significant. Continuous variables were described using a
107 median with interquartile range (IQR). Categorical variables were analyzed using Fisher's exact
108 testing. Two-sample Wilcoxon test was used for continuous variables. To evaluate risk factors
109 associated with antibiotic use, a univariate analysis was conducted and variables with a p-value
110 ≤ 0.05 were included in a multivariate logistic regression.

112 **Results:**

113 A total of 228 encounters met inclusion criteria, with twenty excluded due to
114 asymptomatic disease, leaving 208 encounters included in the final analysis (n=198 patients).
115 The median age was 69 years (IQR 60-80) and 50% (105/208) were male. The most common
116 comorbidities were hypertension (143/208, 69%), obesity (81/208, 39%), and diabetes (81/208,
117 39%). Of the 208 encounters, 83% (172/208) of patients received at least one course of
118 antibiotics (Table 1). Antibiotic prescribing did not differ based on gender, age, race, or
119 comorbidities. Even though a small subset of patients (n=11), all immunocompromised patients
120 received antibiotics

121 While rates of antibiotic prescribing overall were high, we saw a temporal decrease in
122 antibiotic prescribing. When consolidating encounters by month of admission, rates of
123 antibiotic prescribing were highest in March, with 88% (42/49) of encounters receiving
124 antibiotics, compared to 82% (127/155) in April and 75% (3/4) in May.

125 Rates of antibiotic prescribing were significantly higher in patients admitted to the
126 intensive care unit (ICU), requiring O2 support (including ventimask, BiPAP and mechanical
127 ventilation), and with acute respiratory distress syndrome (ARDS) ($p < 0.01$). Median length of
128 stay was 6.5 days longer in those receiving antibiotics ($p < 0.01$). Patients who received
129 investigational or off-label therapy for COVID-19 were also more often prescribed antibiotics (p
130 = 0.03). Patients who died within 28 days were more often prescribed antibiotics (92%, 47/51, p
131 = 0.02). Procalcitonin (PCT) at baseline was higher in those who were prescribed antibiotics ($p <$
132 0.01). In a subgroup analysis, PCT > 0.5 was associated with a higher rate of antibiotic

133 prescribing [94% (44/47) prescribed antibiotics vs. 6% (3/47) did not receive antibiotics, OR
134 3.76, CI 1.09-20.1, $p = 0.03$]. Of patients with a PCT > 0.5, 43/47 had respiratory or blood
135 cultures obtained. Microbiologically confirmed bacterial infection was present in 12% of
136 patients with PCT >0.5 (5/43).

137 Respiratory cultures were obtained in 32% (67/208) of patients. In total, 19% (13/67)
138 were positive (Table 2). *Staphylococcus aureus* was identified in 5 of 13 positive respiratory
139 culture results (3% of total patients). Blood cultures were obtained in the majority of patients
140 (149/208, 72%), but few were positive (12/149, 7%). All influenza PCR and *Legionella* urinary
141 antigen (UAg) tests were negative ($n = 88$ and 93 respectively). Two *Streptococcus pneumoniae*
142 UAg tests were positive (2.4%, 2/84). In addition, 75 patients (36%) were screened for MRSA
143 nares colonization. Overall, there were 24 microbiologically-confirmed infections and all were
144 treated with antibiotics [12% (24/208)]. In a subgroup analysis, patients with microbiologically-
145 confirmed infection were more likely to receive additional courses of antibiotics (20/24, 83% p
146 < 0.01), be admitted to the ICU (23/24, 96%, $p < 0.01$), and have a longer length of stay (median
147 29.5 days, $p < 0.01$).

148 The most frequently prescribed initial antibiotics were ceftriaxone in 113 (66%) patients
149 and azithromycin in 99 (57%) patients for community acquired pneumonia (CAP), followed by
150 an anti-pseudomonal beta lactam (23%) and vancomycin (23%) for hospital acquired
151 pneumonia (HAP) or ventilator associated (VAP) (Figures 1 and 2). The median time from SARS-
152 CoV-2 collection to antibiotic initiation was one day (IQR 1-4.5 days). Median duration of
153 therapy for the initial course of antibiotics was five days (IQR 2-6 days). In 41 (24%) patients,
154 the initial regimen was changed; 17 patients were escalated to broader therapy (42%) and 15

155 patients were de-escalated to narrower therapy (37%). Nine (22%) had another regimen change
156 such as intravenous to oral conversion or transition to another agent with similar spectrum of
157 activity and not based on positive culture result.

158 Fifty-two patients (30%) received a second course of antibiotics and 19 patients (11%)
159 received more than 2 antibiotic courses during hospitalization. The most frequently prescribed
160 antibiotics included an anti-pseudomonal beta lactam (58%) and vancomycin (58%) for
161 HAP/VAP (Figures 1 and 2). The median duration of second course antibiotics was 6 days (IQR 3-
162 8.25). Duration of admission, ICU admission, ICU length of stay (LOS), mechanical ventilation,
163 microbiologically-confirmed infection, and duration of initial course of antibiotics were all risk
164 factors for receiving more than one course of antibiotics (Table 3). Of patients with
165 microbiologically-confirmed infection who received additional antibiotic courses, 14 (70%)
166 received treatment for HAP/VAP, 4 (20%) received treatment for bloodstream infection and 2
167 (10%) received treatment for other infections unrelated to cultures.

168 Discussion

169 In this multi-center study of patients hospitalized with COVID-19, we found an overall
170 high rate of antibiotic prescribing, with 83% of patients receiving antibiotics. Of these patients,
171 30% received at least one additional course of antibiotics within the same hospitalization,
172 increasing the overall antibiotic exposure. Despite the high rate of antibiotic prescribing, there
173 were low rates of bacterial coinfection, with only 12% of patients having microbiologically-
174 confirmed infection for initial antibiotic use. These findings are similar to the results of previous
175 studies, suggesting the need for strategies to help clinicians judiciously prescribe antibiotics in

176 patients with COVID-19.^{1-5, 15} Previous studies conducted in the United States have shown that
177 concomitant community acquired infections in COVID-19 patients are low based on
178 microbiological data within the first 48 hours of admission.^{4, 5} In our study, we found only
179 slightly higher rates of microbiologically-confirmed infections than in other US studies, despite
180 the fact that we reported all microbiologic data throughout hospitalization. The higher rate may
181 be explained by bacterial infections acquired during hospitalization. Patients with
182 microbiologically-confirmed infections were more likely to receive more than one course of
183 antibiotics, be admitted to the ICU, and have a longer length of stay. Additional courses of
184 antibiotics were often prescribed for empiric or targeted treatment of nosocomial infection.

185 Early in the pandemic, little was known regarding COVID-19 presentation, disease
186 progression and rates of bacterial co-infection. Thus, guideline recommendations were evolving
187 throughout the study period. Initial recommendations often encouraged antibiotic use. Within
188 the University of Rochester Medical Center, our practices and institutional guidelines
189 recommended initiating empiric antibiotics in the majority of COVID-19 patients. As information
190 became more available, both national and institutional guidance changed, recommending
191 judicious use of antibiotics. Subsequently, our antibiotic prescribing decreased. This was
192 reflected in the temporal decline in antibiotic prescribing we observed from March to May.

193 There were several indicators that serious illness increased the risk of antibiotic
194 prescribing. Initial antibiotic prescribing was more likely in patients with elevated PCT, longer
195 length of stay, ICU admission, longer ICU length of stay, and administration of off-label or
196 investigational therapy for COVID-19. Additionally, all patients with ARDS or requiring more
197 invasive O2 support received at least 1 course of antibiotics. These findings are consistent with

198 previous studies which found patients were more likely to receive antibiotics if they had severe
199 disease upon presentation.^{4, 5} To our knowledge, this is the first study to report rates of
200 additional antibiotic prescribing beyond initial empiric therapy. Patients with COVID-19 often
201 have a prolonged hospitalization due to the underlying disease process. Our median LOS was
202 significantly longer in patients who received at least one antibiotic course (12 days vs 5.5 days,
203 $p < 0.001$), and prolonged hospitalization may also increase the potential for additional
204 antibiotic exposure. Thus, it is important to understand antibiotic prescribing trends and
205 associated risk factors beyond the first course. Our study found that nearly one-third of all
206 patients received two or more courses of antibiotics. Variables associated with receiving two or
207 more antibiotic courses included: longer length of stay, ICU admission, longer ICU length of
208 stay, and mechanical ventilation. This is likely explained as these are all risk factors for hospital-
209 acquired illness and antibiotics were commonly prescribed for nosocomial infection (e.g.
210 HAP/VAP).

211 Procalcitonin has been suggested as a potentially useful biomarker to differentiate
212 bacterial and viral infections and assist with clinical decision-making. However, the ATS/IDSA
213 CAP guidelines strongly advise initiating antibiotics based off clinical judgement rather than PCT
214 alone.¹³ In alignment with these guidelines, our institution does not recommend routinely using
215 PCT to guide antibiotic initiation for CAP or sepsis. In COVID-19 patients specifically, there are
216 conflicting data regarding baseline PCT in COVID-19 patients.^{4, 16} One two-center study found
217 that patients with PCT available prior to antibiotic initiation were less likely to be prescribed
218 antibiotics.¹⁷ At our sites, the patients prescribed antibiotics had significantly higher baseline
219 PCT, however the median was only 0.28. In a subgroup analysis focusing on patients who had a

220 PCT of > 0.5, 94% of patients (41/44) received antibiotics. Rates of microbiologically confirmed
221 infection were similar between patients with a PCT > 0.5 and the entire cohort (12%). It is
222 unclear at this time the utility of using PCT to determine if there is bacterial co-infection with
223 COVID-19, and in our study it did not appear to be predictive of confirmed infection.

224 Previous studies have shown high rates of broad-spectrum antibiotics for initial empiric
225 therapy in COVID-19 patients.^{1, 3-6, 8, 15} However, in our patient population, most patients were
226 treated initially for CAP. The most common agents included ceftriaxone plus azithromycin,
227 which is consistent with the 2019 ATS/IDSA recommendations for CAP.¹³ It is worth noting that
228 our institution did not routinely recommend use of azithromycin off-label for anti-inflammatory
229 effects in COVID-19. During the initial antibiotic course, 37% of patients were de-escalated to
230 narrower therapy. Not surprisingly, patients who received a second course of antibiotics were
231 more likely to receive broad-spectrum antimicrobials; over half of patients who received more
232 than one course of antibiotics were treated for HAP/VAP and prescribed an anti-pseudomonal
233 beta lactam. Respiratory cultures were obtained in only 30.2% of patients, with a large number
234 of patients receiving empiric treatment for CAP, HAP or VAP. In part, the low number of
235 respiratory cultures obtained may be due to the symptomatology of disease, with the majority
236 of patients experiencing dry, non-productive cough.¹ Additionally, limited PPE early in the
237 pandemic created additional challenges in obtaining respiratory cultures due to concerns of
238 transmission and aerosolization. Also, the 2019 ATS/IDSA CAP guidelines do not recommend
239 routine sputum gram stain and culture in patients with non-severe CAP or those without multi-
240 drug resistant organism risk factors due to overall poor yield and detection of organisms.¹³
241 However, respiratory cultures are recommended in patients being treated empirically for MDR

242 organisms, and in those being treated for HAP/VAP.^{13, 14} Respiratory cultures were not obtained
243 in all patients who met these criteria. Obtaining respiratory cultures and other microbiologic
244 data, when possible, on patients treated with broad spectrum antibiotics can potentially help
245 with de-escalation of therapy.

246 One limitation of this study is its retrospective design. Laboratory and microbiologic
247 data collected were not consistent amongst all patients. We found duration of admission and
248 ICU length of stay to be associated with higher antibiotic use, however it is difficult to say that
249 these are true risk factors for antibiotic prescribing. Instead, this difference was likely due to
250 antibiotic prescribing being higher in patients with more serious illness, and perhaps longer
251 admission leading to increased risk of nosocomial infections and subsequent antibiotic courses.
252 Additionally, we did not perform a time adjusted analysis. Another limitation is that the vast
253 majority of patients within our study received antibiotics which could have affected our ability
254 to detect differences between the two groups. Early in the pandemic, most COVID-19 patients
255 within our institution received antibiotics. While we saw a temporal decrease over time, it is
256 difficult to assess risk factors for antibiotic use in our patients treated for COVID-19 early in the
257 study when antibiotic use was routine.

258 While there were limitations of this study, there were also several strengths. This study
259 was multi-site, including three hospitals within the University of Rochester Medical Center: two
260 community hospitals and a tertiary academic medical center. Therefore, the results of this
261 study may be generalizable to similar sites. Finally, as previously mentioned, this is the first
262 study to assess overall antibiotic use throughout hospitalization, and determine risk factors for
263 additional antibiotic courses. Many patients with COVID-19 have prolonged hospitalization,

264 increasing the risk for antibiotic exposure. Our study examined antibiotic use that is more
265 representative of hospitalized COVID-19 patients. Based on the results of this study, our
266 institution plans to examine how other factors may increase or decrease the risk of antibiotic
267 prescribing, as well as trend our use of antibiotics throughout the pandemic.

268 **Conclusions**

269 Our study found high rates of antibiotic prescribing, despite low rates of respiratory
270 cultures and confirmed microbiologic infections. Nearly one-third of patients were treated with
271 more than one antibiotic course during hospitalization. These data highlight a role for
272 antimicrobial stewardship during the COVID-19 pandemic. Further studies are needed to
273 examine the impact of antimicrobial stewardship initiatives in patients with COVID-19 and
274 assess if antibiotic prescribing practices have changed with increasing information related to
275 bacterial co-infection that wasn't available at the beginning of the pandemic.

276

277

278

279

280

281

282

283

284

285

286

287 **References:**

- 288 1. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-
289 19 in Wuhan, China: a retrospective cohort study. *Lancet* (London, England) 2020;10229:1054-62.
- 290 2. Crotty MP, Dominguez EA, Akins R, et al. Investigation of subsequent and co-infections associated
291 with SARS-CoV-2 (COVID-19) in hospitalized patients. *medRxiv* 2020.
- 292 3. Rawson TM, Moore LSP, Zhu N, et al. Bacterial and fungal co-infection in individuals with coronavirus:
293 A rapid review to support COVID-19 antimicrobial prescribing. *Clinical infectious diseases : an official
294 publication of the Infectious Diseases Society of America* 2020.
- 295 4. Vaughn VM, Gandhi T, Petty LA, et al. Empiric Antibacterial Therapy and Community-onset Bacterial
296 Co-infection in Patients Hospitalized with COVID-19: A Multi-Hospital Cohort Study. 2020.
- 297 5. Wei W, Ortwine JK, Mang NS, Joseph C, Hall BC, Prokesch BC. Limited Role for Antibiotics in COVID-
298 19: Scarce Evidence of Bacterial Coinfection. Available at SSRN 3622388 2020.
- 299 6. Beović B, Doušak M, Ferreira-Coimbra J, et al. Antibiotic use in patients with COVID-19: a 'snapshot'
300 Infectious Diseases International Research Initiative (ID-IRI) survey. *Journal of Antimicrobial
301 Chemotherapy* 2020.
- 302 7. Buehrle DJ, Decker BK, Wagener MM, et al. Antibiotic consumption and stewardship at a hospital
303 outside of an early Coronavirus disease 2019 epicentre. 2020;AAC.01011-20.
- 304 8. Abelenda-Alonso G, Padullés A, Rombauts A, et al. Antibiotic prescription during the COVID-19
305 pandemic: A biphasic pattern. *Infection Control & Hospital Epidemiology* 2020;1-2.
- 306 9. Nestler M, Godbout E, Lee K, et al. Impact of COVID-19 on Pneumonia-Focused Antibiotic Use at an
307 Academic Medical Center. *Infection control and hospital epidemiology* 2020;1-9.
- 308 10. COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines.
309 "Government Document"
- 310 11. Clinical management of COVID-19 Interim Guidance - May 2020, Available from
311 <https://www.who.int/publications-detail/clinical-management-of-covid-19>. 2020.
- 312 12. Alhazzani W, Møller MH, Arabi YM, et al. Surviving Sepsis Campaign: guidelines on the management
313 of critically ill adults with Coronavirus Disease 2019 (COVID-19). *Intensive care medicine* 2020;5:854-87.
- 314 13. Metlay JP, Waterer GW, Long AC, et al. Diagnosis and Treatment of Adults with Community-
315 acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and
316 Infectious Diseases Society of America. 2019;7:e45-e67.
- 317 14. Kalil AC, Metersky ML, Klompas M, et al. Management of Adults With Hospital-acquired and
318 Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of
319 America and the American Thoracic Society. *Clinical Infectious Diseases* 2016;5:e61-e111.
- 320 15. Lansbury L, Lim B, Baskaran V, Lim WS. Co-infections in people with COVID-19: a systematic review
321 and meta-analysis. *The Journal of infection* 2020;2:266-75.
- 322 16. Bass J, Singh A, Williams R, Lindner DH. Procalcitonin and COVID-19: A Reliable Clinical Tool. 2020.
- 323 17. Pulia MS, Wolf I, Schwei RJ, et al. Antibiotic Prescribing Patterns for COVID-19 in Two Emergency
324 Departments with Rapid Procalcitonin. 2020;1-7.

325

326

327

328

329

Tables

Baseline Characteristic	Total	Antibiotics n=172	No Antibiotics n=36	P-value
Male gender	105 (50.5)	84 (48.8)	21 (55.6)	0.43
Age, years (median, IQR)	69.0 (60-80)	70.0 (61-81)	65.5 (47-77)	0.12
Race				0.56
Caucasian	116 (55.7)	98 (56.9)	18 (47.2)	
Black/African American	69 (33.2)	53 (30.8)	16 (44.4)	
Asian	2 (1.0)	2 (1.2)	0 (0)	
Other	6 (2.9)	6 (3.5)	0 (0)	
Unknown	15 (7.2)	13 (7.6)	2 (5.6)	
Comorbidities				
Hypertension	143 (68.8)	116 (67.4)	27 (72.2)	0.43
Diabetes	81 (38.9)	70 (23.2)	11 (27.8)	0.35
Obesity	80 (38.5)	66 (38.4)	14 (38.9)	>0.99
Cardiac Disease	56 (26.9)	50 (29.1)	6 (16.7)	0.15
Chronic Lung Disease	43 (20.7)	37 (21.5)	6 (16.7)	0.65
CKD	45 (21.7)	40 (23.2)	5 (13.9)	0.20
None	21 (10.1)	17 (9.9)	4 (11.1)	0.77
Immunocompromised ^a	11 (5.3)	11 (6.4)	0 (0)	0.22
Labs (median, IQR)				
AST, U/L	43 (31-65)	46 (33.25-65)	35 (26.75-49)	0.02
ALT, U/L	30 (20-46)	29.5 (20-45)	32.5 (20-49.5)	0.83
Scr, mg/dL	1.130 (0.84-1.64)	1.14 (0.84-1.725)	1.06 (0.81-1.3)	0.14
WBC, /mm ³	7.30 (5.50-10.50)	7.4 (5.5-10.7)	6.8 (4.8-9.2)	0.11
ALC, K/uL	1.0 (0.7-1.3)	1.0 (0.7-1.3)	1.1 (0.5-1.4)	0.10
CRP, mg/L	93.0 (39.5-134.5)	93 (39.5-134.5)	73 (37.5-118.5)	0.37
LDH, U/L	344 (264.5-467)	348 (285-474)	294 (239-387)	0.03
Ferritin, ng/mL	627 (304-1086)	627 (309-1133.5)	589 (235-980)	0.45
D-dimer, ug/mL	1.26 (0.63-2.08)	1.37 (0.71-2.1)	0.86 (0.6-1.6)	0.24
PCT, ng/mL	0.215 (0.120-0.620)	0.28 (0.13-0.63)	0.13 (0.09-0.20)	<0.01
Symptoms Prior to Admission				
Fever	120 (57.7)	101 (58.7)	19 (52.8)	0.59
Respiratory Symptoms	180 (86.5)	152 (88.4)	28 (75)	0.10

Gastrointestinal symptoms	76 (36.5)	60 (34.9)	16 (41.7)	0.34
Anosmia/Hyposmia/Hypogeusia	11 (5.3)	10 (5.8)	1 (2.8)	0.69
Symptom duration prior to admission, days (median, IQR)	6.0 (3-9)	6.0 (3-9)	7.5 (4.75-9)	0.16
Location prior to admit				0.08
Home	140 (67.3)	110 (63.9)	30 (80.5)	
SNF	60 (28.8)	54 (31.4)	6 (16.7)	
Transfer from OSH	8 (3.8)	8 (4.7)	0 (0)	
Duration of admission, days (median, IQR)	11 (5-22)	12 (5.75-25)	5.5 (4-11.3)	<0.01
ICU admission	104	102 (58.9)	2 (5.6)	<0.01
ICU LOS, days (median, IQR)	10 (3-18)	10 (3.25-18)	6.5 (6.25-6.75)	0.59
O2 support				<0.01
Room Air	40 (19.2)	24 (13.9)	16 (44.4)	
Standard Nasal Cannula	67 (32.2)	49 (28.5)	18 (50.0)	
HFNC/Venti Mask	19 (9.1)	17 (9.9)	2 (5.6)	
BiPAP	5 (2.4)	5 (2.9)	0 (0)	
Non-rebreather	7 (3.4)	7 (4.1)	0 (0)	
Mechanical ventilation	70 (33.7)	70 (40.7)	0 (0)	
ARDS	78 (37.5)	78 (45.3)	0 (0)	<0.01
Received investigational or off-label treatment for COVID-19 ^b	37 (17.8)	35 (20.2)	2 (5.6)	0.03
28-day mortality	51 (24.5)	48 (27.9)	3 (8.3)	0.02
30-day readmission	16 (7.7)	12 (6.9)	4 (11.1)	0.75
More than 1 admission for COVID-19	12 (5.8)	8 (4.7)	4 (11.1)	0.23
Time from discharge to COVID-19 readmission, days (median, IQR)	7 (4.5-12.25)	5 (2.75-11.5)	10 (7.75-12.5)	0.22

(%) = Percentages unless otherwise specified

a = immunocompromised patients were defined as those with previous solid organ transplant, active cancer receiving chemotherapy, patients on biologic therapy, and uncontrolled HIV

b = Investigational or off-label therapy included remdesivir, remdesivir + baricitinib, hydroxychloroquine, tocilizumab or convalescent plasma

IQR = Interquartile Range

CKD = chronic kidney disease

AST = Aspartate aminotransferase

ALT = Alanine aminotransferase

SCr = Serum Creatinine

WBC = White blood cell count

ALC = Absolute lymphocyte count

CRP = C-reactive protein

LDH = Lactate dehydrogenase

PCT = procalcitonin

SNF = Skilled nursing facility

HFNC = high flow nasal cannula

Respiratory symptoms were defined as hypoxia, SOB, cough

GI symptoms were defined as nausea, vomiting, diarrhea

Table 2: Microbiologic Data			
Micro Data	Antibiotics n=172	No antibiotics n=36	P-value
Microbiologically-confirmed infection	24 (14.0)	0 (0)	0.02
Respiratory cultures obtained	66 (38.3)	1 (2.7)	<0.01
No growth	53 [80.3]	1 [100]	>0.99
Positive	13 [19.7]	0 [0]	>0.99
Blood cx obtained	135 (78.5)	14 (38.9)	<0.01
No growth	123 [91.1]	14 [100]	0.61
Positive	12 [8.9]	0 [0]	0.61
Influenza PCR obtained	75 (43.6)	13 (36.1)	0.46
Strep pneumoniae urinary antigen obtained	82 (47.7)	6 (16.7)	<0.01
Positive	2 [2.4]	0 [0]	>0.99
Negative	80 [97.6]	6 [100]	>0.99
Legionella urinary antigen obtained	87 (50.5)	6 (16.7)	<0.01
MRSA nares obtained	73 (42.4)	2 (5.6)	<0.01
Positive	4 [5.5]	0 [0]	>0.99
Negative	69 [94.5]	2 [100]	>0.99

Variable	Univariate Analysis			Multivariate analysis		
	1 antibiotic course n= 120 (%)	> 1 antibiotic course n=52 (%)	P value	Odds ratio	95% CI	P-value
Length of stay, days (median, IQR)	8 (4-15)	25 (18.75-37)	<0.01	1.01	0.99-1.04	0.32
ICU admission	51 (42.5)	49 (94.2)	<0.01	1.96	0.38-11.10	0.42
ICU length of stay, days (median, IQR)	5 (3-9)	18 (12-26)	<0.01	1.14	1.06-1.26	<0.01
Mechanical ventilation	25 (20.8)	45 (86.5)	<0.01	1.83	0.46-7.61	0.39
More than 1 COVID-19 related admission	7 (5.8)	1 (1.9)	0.44			
Microbiologically-confirmed infection	4 (3.3)	20 (38.5)	<0.01	3.31	0.86-15.26	0.10
Duration of initial course of antibiotics, days (median, IQR)	4 (2-5.25)	5 (4-7)	<0.01			
Time from SARS-CoV-2 collect date to initial antibiotic start, days (median, IQR)	1 (0-5)	2 (0-2)	0.51			
28-day mortality	33 (27.5)	14 (38.9)	>0.99			


()= Percentages unless otherwise specified

330

331


332

333 **Figures**



334

335



336

337

338